
|Articles|April 10, 2008
Abatacept approved by FDA for use in children
Bristol-Myers Squibb granted approval for arthritis biologic Orencia.
Advertisement
Children ages six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) may now get some relief from using abatacept (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
Vaccine Policy in Flux: Stories Pharmacists Need to Follow
3
Pharmacists Are Essential Drivers of Opioid Stewardship Programs
4
Q&A: Pharmacists Help Patients Navigate Pneumococcal Vaccine Options
5






























